Journal article · 2012 · Open access

Big Pharma, little science?

Ismael Ràfols, Michael M. Hopkins, Jarno Hoekman, Josh Siepel, Alice O’Hare, Antonio Perianes‐Rodríguez, Paul Nightingale

Technological Forecasting and Social Change, 81, 22–38 · Published 24 July 2012 · DOI 10.1016/j.techfore.2012.06.007

Open PDFView at the publisherCite this paper

In brief

“Big Pharma, little science?” is a 2012 journal article by Ismael Ràfols and 6 co-authors, published in Technological Forecasting and Social Change. OpenAlex counts 150 citations as of 22 November 2026, which puts it in the top 3% of works published in 2012 by citations. It is open access under a public domain licence: the full text is free to read at Technological Forecasting and Social Change.

Citations
150
Most cited in
2023 (17)
Field-weighted impact
16.61
References
79
Authors
7

Abstract

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms (Big Pharma) during the period 1995–2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by Big Pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that Big Pharma are increasingly becoming ‘network integrators’ rather than the prime locus of drug discovery.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ràfols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O’Hare, A., Perianes‐Rodríguez, A., & Nightingale, P. (2012). Big Pharma, little science? Technological Forecasting and Social Change, 81, 22–38. https://doi.org/10.1016/j.techfore.2012.06.007

MLA 9

Ràfols, Ismael, et al. “Big Pharma, little science?” Technological Forecasting and Social Change, vol. 81, 2012, pp. 22–38. https://doi.org/10.1016/j.techfore.2012.06.007.

Chicago

Ràfols, Ismael, Michael M. Hopkins, Jarno Hoekman, Josh Siepel, Alice O’Hare, Antonio Perianes‐Rodríguez, and Paul Nightingale. 2012. “Big Pharma, little science?” Technological Forecasting and Social Change 81: 22–38. https://doi.org/10.1016/j.techfore.2012.06.007.

Harvard

Ràfols, I. et al. (2012) ‘Big Pharma, little science?’, Technological Forecasting and Social Change, 81, pp. 22–38. doi:10.1016/j.techfore.2012.06.007.

IEEE

I. Ràfols et al., “Big Pharma, little science?,” Technological Forecasting and Social Change, vol. 81, pp. 22–38, 2012, doi: 10.1016/j.techfore.2012.06.007.

BibTeX

@article{rafols2012pharma,
  title     = {{Big Pharma, little science?}},
  author    = {Ràfols, Ismael and Hopkins, Michael M. and Hoekman, Jarno and Siepel, Josh and O’Hare, Alice and Perianes‐Rodríguez, Antonio and Nightingale, Paul},
  journal   = {Technological Forecasting and Social Change},
  year      = {2012},
  volume    = {81},
  pages     = {22--38},
  doi       = {10.1016/j.techfore.2012.06.007},
  url       = {https://doi.org/10.1016/j.techfore.2012.06.007}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171212
20181111
201977
20201212
20211414
20221313
20231717
20241111
202599
202644

Its field-weighted citation impact is 16.61: it has been cited 16.61 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy

  • pharmaceutical R&D
  • Big Pharma
  • R&D productivity
  • drug discovery
  • scientific publications
  • external collaboration
  • R&D outsourcing
  • emerging markets

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Ràfols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O’Hare, A., Perianes‐Rodríguez, A., & Nightingale, P. (2012). Big Pharma, little science? Technological Forecasting and Social Change, 81, 22–38. https://doi.org/10.1016/j.techfore.2012.06.007

How many times has this paper been cited?

150 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Technological Forecasting and Social Change: sign in and open the PDF from this page.

Who wrote this paper?

Ismael Ràfols, Michael M. Hopkins, Jarno Hoekman, Josh Siepel, Alice O’Hare, Antonio Perianes‐Rodríguez, Paul Nightingale.

What is the DOI of this paper?

10.1016/j.techfore.2012.06.007, permanently at https://doi.org/10.1016/j.techfore.2012.06.007. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.